EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.
Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al.
Pediatric Blood and Cancer.
2020;
67.
Abnormal Newborn Screening Follow-up for Severe Combined Immunodeficiency in an Amish Cohort with Cartilage-Hair Hypoplasia.
Scott, EM; Chandra, S; Li, J; Robinette, ED; Brown, MF; Wenger, OK.
Journal of Clinical Immunology.
2020;
40:321-328.
The Value of Chromosome Analysis to Interrogate Variants in DNMT3B Causing Immunodeficiency, Centromeric Instability, and Facial Anomaly Syndrome Type I (ICF1).
Kellner, ES; Rathbun, PA; Marshall, GS; Tolusso, LK; Smolarek, TA; Sun, M; Chandra, S; Bleesing, J; Marsh, RA.
Journal of Clinical Immunology.
2019;
39:857-859.
Primary immune regulatory disorders for the pediatric hematologist and oncologist: A case-based review.
Chandrakasan, S; Chandra, S; Saldana, BJ D; Torgerson, TR; Buchbinder, D.
Pediatric Blood and Cancer.
2019;
66:e27619-e27619.
The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018).
Dvorak, CC; Haddad, E; Buckley, RH; Cowan, MJ; Logan, B; Griffith, LM; Kohn, DB; Pai, S; Notarangelo, L; Shearer, W; et al.
Journal of Allergy and Clinical Immunology.
2019;
143:405-407.
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.
Haddad, E; Logan, BR; Griffith, LM; Buckley, RH; Parrott, RE; Prockop, SE; Small, TN; Chaisson, J; Dvorak, CC; Mumane, M; et al.
Blood.
2018;
132:1737-1749.
Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.
Chandra, S; Fukuda, T; Mizuno, K; Davies, SM; Teusink-Cross, A; Tarin, R; Marsh, RA; Vinks, AA; Mehta, PA.
Journal of Antimicrobial Chemotherapy.
2018;
73:1651-1658.
Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno, K; Dong, M; Fukuda, T; Chandra, S; Mehta, PA; McConnell, S; Anaissie, EJ; Vinks, AA.
Clinical Pharmacokinetics.
2018;
57:625-636.
Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
Silva, JM F; Ladomenou, F; Carpenter, B; Chandra, S; Sedlacek, P; Formankova, R; Grandage, V; Friswell, M; Cant, AJ; Nademi, Z; et al.
Blood Advances.
2018;
2:777-786.
Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: A PIDTC natural history study.
Heimall, J; Logan, BR; Cowan, MJ; Notarangelo, LD; Griffith, LM; Puck, JM; Kohn, DB; Pulsipher, MA; Parikh, S; Martinez, C; et al.
Blood.
2017;
130:2718-2727.